Hologic ( (HOLX) ) has released its Q1 earnings. Here is a breakdown of the information Hologic presented to its investors.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Hologic, Inc. is a medical technology company primarily focused on enhancing women’s health through innovative solutions in diagnostics, breast health, and surgical products.
In its first-quarter fiscal 2025 earnings report, Hologic announced a slight revenue increase of 0.9% to $1.0218 billion, with a non-GAAP diluted EPS of $1.03, aligning with the high end of its guidance. The company noted that the strengthening of the U.S. dollar impacted its reported results.
Key highlights include a 5.1% increase in diagnostics revenue, driven by molecular diagnostics sales, contrasted by a decline in breast health revenue due to lower sales in mammography equipment. The company also completed the acquisition of Gynesonics, aiming to expand its surgical portfolio. Despite challenges in breast health and currency headwinds, Hologic maintained strong cash flow and repurchased 6.8 million shares.
Looking forward, Hologic has lowered its full-year guidance for GAAP EPS but maintains its non-GAAP EPS outlook, reflecting resilience in its U.S. diagnostics business and strategic capital allocation. The company remains focused on navigating currency challenges while capitalizing on growth opportunities in diagnostics.
